New drug aims to stop lung transplant failure in its tracks
NCT ID NCT06476132
First seen Jan 22, 2026 · Last updated May 13, 2026 · Updated 10 times
Summary
This study tests whether the drug Belumosudil can prevent chronic lung allograft dysfunction (CLAD), a form of long-term rejection, in 234 lung transplant recipients who show early signs of lung injury on biopsy. Participants will take Belumosudil or a placebo for 52 weeks alongside their usual anti-rejection medications. The goal is to see if the drug can delay or prevent CLAD, the need for a new lung transplant, or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center (Site #: 71017)
RECRUITINGCincinnati, Ohio, 45229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cleveland Clinic (Site #: 71101)
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Duke University (Site #: 71139)
RECRUITINGDurham, North Carolina, 27710, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johns Hopkins (Site #: 71119)
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NYU Langone Health (Site #: 71177)
RECRUITINGNew York, New York, 10016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford University (Site #: 71141)
RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Health Network/Toronto General Hospital (Site #: 71121)
RECRUITINGToronto, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California, Los Angeles (Site #: 71123)
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Minnesota (Site 71151)
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pennsylvania (Site #: 71111)
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Vanderbilt University Medical Center (Site #: 71174)
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University (Site #: 71157)
RECRUITINGSt Louis, Missouri, 63130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.